| Project/Area Number |
14571335
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | The Jikei University School of Medicine |
|---|
Principal Investigator |
JOKI Tatsuhiro The Jikei University School of Medicine, Lecturer, 医学部, 講師 (30226378)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ARAI Takao The Jikei University School of Medicine, Assistant, 医学部, 助手 (40307400)
|
|---|
| Project Period (FY) |
2002 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2005: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2004: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2003: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2002: ¥900,000 (Direct Cost: ¥900,000)
|
|---|
| Keywords | Brain Tumor / DDS / Local Therapy / Polymer / 局所療法 / 選択的COX-2阻害薬 / ドキソルビシン / ゲフィニチブ / Drug Delivery System / 温度可変性ポリマー / エンドスタチン / COX-2 / アドリアマイシン / NS398 |
|---|
| Research Abstract |
Many approaches to local tumor treatment have been reported and its efficacy demonstrated in patients with malignant glioma. We studied thermoreversible gelation polymer (TGP) as a novel drug delivery system (DDS) in treating this tumor. TGP exhibits sol-gel transition i.e., is water-soluble in the sol phase below the sol-gel transiting temperature which we can set up as we choose and water-insoluble in the gel phase above this temperature. We conjugated doxorubicin with TGP to prepare doxorubicin-TGP (DXR-TGP) then studied the kinetics of doxorubicin release from TGP and the antitumor activity of DXR-TGP in vitro and in vivo. Diffusive speed of doxorubicin in from TGP at was 9.4 x 10^<-7> cm^2/sec and doxorubicin was released from TGP whenever DXR-TGP was added. DXR-TGP showed antitumor activity with the human glioma cell lines T98G and U87MG and in a subcutaneous tumor model of nude mice. Pathologically, the proliferation marker MIB-1 labeling of the control group was 60-70% and that of the DXR-TGP group 30-40%. This is to our knowledge, the first report of TGP being applied to DDSs, and this report shows some possibility of using TGP as novel DDS for malignant glioma.
|
